CRNX Crinetics Pharmaceuticals Inc

$29.74

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/18/2025

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapies for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California.

Website: https://www.crinetics.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1658247
Address
10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA, US
Valuation
Market Cap
$2.83B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
2.14
Performance
EPS
$-3.69
Dividend Yield
—
Profit Margin
0.00%
ROE
-32.00%
Technicals
50D MA
$33.29
200D MA
$47.24
52W High
$62.53
52W Low
$24.10
Fundamentals
Shares Outstanding
93M
Target Price
$75.36
Beta
0.38

CRNX EPS Estimates vs Actual

● Estimated
● Actual

CRNX News & Sentiment

Aug 08, 2025 • Motley Fool SOMEWHAT-BULLISH
Crinetics ( CRNX ) Q2 Revenue Jumps 150%
Crinetics Pharmaceuticals ( NASDAQ:CRNX ) , a biotechnology company focused on developing oral therapies for rare endocrine diseases, reported its latest quarterly results on August 7, 2025, for the second quarter of fiscal 2025.
Aug 07, 2025 • Zacks Commentary NEUTRAL
Crinetics Pharmaceuticals, Inc. ( CRNX ) Reports Q2 Loss, Lags Revenue Estimates
CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of -8.85% and -79.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Jul 31, 2025 • Zacks Commentary NEUTRAL
Earnings Preview: Crinetics Pharmaceuticals, Inc. ( CRNX ) Q2 Earnings Expected to Decline
CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jul 14, 2025 • Benzinga NEUTRAL
Crinetics Reports Durable Symptom, Hormone Control With Oral Drug In Acromegaly - Crinetics Pharmaceuticals ( NASDAQ:CRNX )
IGF-1 levels remained stable at week 96 for PATHFNDR-1 patients switched to oral palsonify. Daily symptom flares dropped from over 30% on injectables to 6.2% with palsonify in PATHFNDR-1. Get daily-updated rankings across momentum, growth, value, trends, and quality to spot the strongest stocks ...
Jul 13, 2025 • GlobeNewswire NEUTRAL
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ ( Paltusotine ) in Acromegaly at ENDO 2025
Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATHFNDR-2 studies ...
Jul 11, 2025 • GlobeNewswire NEUTRAL
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
SAN DIEGO, July 11, 2025 ( GLOBE NEWSWIRE ) -- Crinetics Pharmaceuticals, Inc. ( Nasdaq: CRNX ) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025 after the market closes. Company management will host a conference call at 4:30 p.m.
Sentiment Snapshot

Average Sentiment Score:

0.153
50 articles with scored sentiment

Overall Sentiment:

Bullish

CRNX Reported Earnings

Feb 26, 2025
Dec 31, 2024 (Pre market)
0.01 Surprise
  • Reported EPS: $-0.88
  • Estimate: $-0.89
  • Whisper: —
  • Surprise %: 1.3%
Nov 12, 2024
Sep 30, 2024 (Post market)
-0.05 Surprise
  • Reported EPS: $-0.96
  • Estimate: $-0.91
  • Whisper: —
  • Surprise %: -5.5%
Aug 08, 2024
Jun 30, 2024 (Post market)
-0.08 Surprise
  • Reported EPS: $-0.94
  • Estimate: $-0.86
  • Whisper: —
  • Surprise %: -9.3%
May 09, 2024
Mar 31, 2024 (Post market)
-0.12 Surprise
  • Reported EPS: $-0.93
  • Estimate: $-0.81
  • Whisper: —
  • Surprise %: -14.8%
Feb 28, 2024
Dec 31, 2023 (Post market)
-0.04 Surprise
  • Reported EPS: $-0.90
  • Estimate: $-0.86
  • Whisper: —
  • Surprise %: -4.7%
Nov 07, 2023
Sep 30, 2023 (Post market)
-0.15 Surprise
  • Reported EPS: $-1.01
  • Estimate: $-0.86
  • Whisper: —
  • Surprise %: -17.4%
Aug 08, 2023
Jun 30, 2023 (Pre market)
-0.08 Surprise
  • Reported EPS: $-0.94
  • Estimate: $-0.86
  • Whisper: —
  • Surprise %: -9.3%
May 04, 2023
Mar 31, 2023 (Post market)
-0.04 Surprise
  • Reported EPS: $-0.85
  • Estimate: $-0.81
  • Whisper: —
  • Surprise %: -4.9%
Feb 28, 2023
Dec 31, 2022 (Post market)
-0.02 Surprise
  • Reported EPS: $-0.84
  • Estimate: $-0.82
  • Whisper: —
  • Surprise %: -2.4%

Financials